Danaher's second quarter 2026 revenue of $6.3B beat estimates, prompting a raised full-year EPS guidance.

Danaher reported second quarter 2026 revenue of $6.3 billion, an increase of 5.5% year-over-year, with non-GAAP adjusted diluted EPS growing 8.0% to $1.94. The company increased its full-year 2026 adjusted EPS guidance.

Key Highlights

• Non-GAAP core revenue grew 3.0% year-over-year, while core revenue excluding the impact of respiratory testing increased 4.5%.
• Management raised its full-year 2026 adjusted diluted EPS guidance to a range of $8.45 to $8.60, up from the previous range of $8.35 to $8.55.
• While bioprocessing revenue was impacted by customer project timing, the company noted that underlying bioprocessing orders grew in the mid-teens during the quarter, signaling a strong recovery trend.